Johnson & Johnson 2006 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2006. Johnson & Johnson is a global healthcare company with approximately 122,200 employees and over 250 operating companies in virtually all countries. The company operates through three primary segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. A significant corporate event occurred on December 20, 2006, with the completion of the acquisition of the Consumer Healthcare business of Pfizer Inc., adding major brands such as Listerine, Nicorette, and Sudafed.
Key Financial Metrics
The provided text contains limited specific financial data for the full fiscal year, as detailed tables are incorporated by reference to the Annual Report. However, the following specific metrics are disclosed:
- Research and Development (R&D): Costs amounted to $7,125 million for 2006, compared to $6,462 million in 2005 and $5,344 million in 2004.
- Product Revenue Concentration: Risperdal/Risperdal Consta accounted for approximately 8% of total revenues; Procrit/Eprex accounted for 6%.
- Patent Expiration Impact: Combined sales of Duragesic/Fentanyl Transdermal and Eprex accounted for approximately 5% of worldwide sales in 2006. Duragesic sales declined 18.3% to $1.3 billion due to generic competition.
- Stock Repurchases: In Q4 2006, the company repurchased 3,696,019 shares under a publicly announced program at an average price of $66.08. The $5 billion repurchase program authorized in March 2006 was completed in Q4 2006.
- Valuation Accounts: Total valuation and qualifying accounts (including rebates, returns, promotions, and doubtful accounts) ended the year at $2,969 million.
Note: Total revenue, net income, cash flow, debt, and liquidity figures are not explicitly stated in the provided text segments.
Material Changes and Operational Highlights
- Acquisition: The acquisition of Pfizer's Consumer Healthcare business was completed in Q4 2006. While the assets represented 26% of total assets, operating results were not significant for 2006 and will be reported starting in 2007.
- Patent Cliffs: Duragesic lost basic patent protection in 2004-2006, leading to an 18.3% sales decline in 2006. Eprex lost protection in international markets, though generic competition is expected to be limited in the near term.
- Upcoming Expirations: Material patents for Risperdal (expiring Dec 2007) and Topamax (expiring Sept 2008) are scheduled to expire within two years. The company is seeking pediatric extensions to maintain exclusivity.
- Executive Changes: Robert J. Darretta retired as CFO effective December 31, 2006. Dominic J. Caruso was named CFO effective January 1, 2007. Michael J. Dormer, Worldwide Chairman of Medical Devices, retired in February 2007.
Outlook, Risks, and Contingencies
Regulatory Environment: The company faces increasing scrutiny regarding drug pricing, reimbursement levels (specifically under the Medicare Prescription Drug, Improvement and Modernization Act of 2003), and business practices. Regulatory agencies have powers to enforce product withdrawals, recalls, and sanctions.
Legal Proceedings: The company is involved in various proceedings under the Comprehensive Environmental Response, Compensation and Liability Act (Superfund). Management does not believe these will have a material adverse effect on operations or financial position.
Internal Controls: Management concluded that internal controls over financial reporting were effective as of December 31, 2006. The Pfizer Consumer Healthcare business was excluded from this assessment due to the timing of the acquisition.
Market Risk: The filing references quantitative and qualitative disclosures about market risk in the Annual Report but does not provide specific data in the text provided.
Investor Verification Checklist
- Verify the full-year 2006 revenue, net income, and cash flow figures in the "Selected Financial Data" and "Consolidated Statements of Earnings" (incorporated by reference).
- Review the impact of the Pfizer Consumer Healthcare acquisition on 2007 guidance and segment reporting.
- Assess the timeline and success of pediatric exclusivity extensions for Risperdal and Topamax to mitigate patent cliff risks.
- Examine the "Legal Proceedings" note (Note 18) for details on environmental liabilities and product liability litigation.
- Confirm the status of the $5 billion stock repurchase program completion and future capital allocation plans.